The News Review:
- Company Profile for Illumina Inc.(Company overview)
- Map Pharmaceuticals names first medical chief Silicon Valley / San…
- Authors’ response to “The two best reasons NT to focus on…
Company Profile for Illumina Inc.(Company overview)
Free with registration – Business Wire – AccessMyLibrary.com – Aug 10, 2007
(Company overview) –>CPYRIGHT 2007 Business Wire Illumina is a leading developer manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using proprietary technologies Illumina provides a comprehensive line of products and services that serve the sequencing genotyping and gene expression markets. Customers include leading genomic. CPYRIGHT 2007 Business Wire.
Map Pharmaceuticals names first medical chief Silicon Valley / San…
Bizjournals.com – Aug 10, 2007
Shashidhar Kori as vice president of clinical development. Shrewsbury was vice president of clinical and regulatory affairs before his promotion. In his new job he will oversee all medical and business aspects of clinical research and development. He'll also speak for the company on medical matters. Shrewsbury has a medical degree in medicine and surgery from Liverpool University. Kori worked most recently at GlaxoSmithKline where he was senior medical adviser in the pain and migraine program. San Francisco Business Times.
Authors’ response to “The two best reasons NT to focus on…
Nature.com – Nature.com (subscription) – Aug 10, 2007
We respectfully disagree however with Dr Graves’ interpretation of the results of the Modification of Diet in Renal Disease (MDRD) study. As discussed in our original article (citation above) a number of caveats have been reported in subsequent analyses leading to consideration of the MDRD study as being “inconclusive” rather than negative. P values as low as 0. 07 in clinical research are considered by many to be indicative of a significantly beneficial intervention that is worthy of being proposed to patients. Many other medications are given to patients without such a level of statistical confidence. Far from ignoring the MDRD data we used it in our meta-analysis. 1 ne of well-accepted strengths of a meta-analysis is to take the ‘essence’ of clinical trials and correct for insufficient power (of individual trials) by increasing the number of observations.
